Analysts See Daiichi Sankyo Exercising Light Control Of Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Japan's Daiichi Sankyo will let the current management of India's top drug firm Ranbaxy Laboratories have a free hand in pursuing new ties-ups and expanding generic sales globally following the model set by Novartis-Sandoz, analysts say